MM120 (LSD D-Tartrate)
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Major Depressive Disorder
Conditions
Major Depressive Disorder
Trial Timeline
Apr 14, 2025 → May 1, 2027
NCT ID
NCT06941844About MM120 (LSD D-Tartrate)
MM120 (LSD D-Tartrate) is a phase 3 stage product being developed by Definium Therapeutics for Major Depressive Disorder. The current trial status is active. This product is registered under clinical trial identifier NCT06941844. Target conditions include Major Depressive Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Major Depressive Disorder were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06941844 | Phase 3 | Active |
| NCT06809595 | Phase 3 | Recruiting |
| NCT06741228 | Phase 3 | Recruiting |
Competing Products
20 competing products in Major Depressive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 26 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| LY2216684 | Eli Lilly | Phase 1 | 29 |
| Duloxetine | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 29 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 40 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 40 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 35 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| FK949E | Astellas Pharma | Phase 1 | 29 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 43 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 35 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 39 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 42 |
| LY2216684 + Sertraline | Eli Lilly | Phase 1 | 29 |
| LY2216684 + Placebo + Lorazepam | Eli Lilly | Phase 1 | 29 |
| LY2216684 + SSRI | Eli Lilly | Phase 3 | 40 |